Cti Biopharma Corp CTIC
We take great care to ensure that the data presented and summarized in this overview for CTI BIOPHARMA CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CTIC
Top Purchases
Top Sells
About CTIC
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Insider Transactions at CTIC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2023
|
Bvf Partners L P Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,569,286
-100.0%
|
$14,123,574
$9.1 P/Share
|
|
Jun 26
2023
|
Bvf Partners L P Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,286,874
-100.0%
|
$65,581,866
$9.1 P/Share
|
|
Jun 26
2023
|
James K Fong EVP & Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,565
-100.0%
|
$32,085
$9.1 P/Share
|
|
Jun 26
2023
|
Adam R Craig President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
31,470
-100.0%
|
$283,230
$9.1 P/Share
|
|
Jun 26
2023
|
David Kirske EVP, Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,547
-100.0%
|
$157,923
$9.1 P/Share
|
|
Jun 26
2023
|
Reed Vaughn Tuckson Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
48,639
-100.0%
|
$437,751
$9.1 P/Share
|
|
Jun 26
2023
|
Matthew D Perry Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
43,139
-100.0%
|
$388,251
$9.1 P/Share
|
|
Jan 24
2023
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
85,317
-40.29%
|
$511,902
$6.01 P/Share
|
|
Jan 24
2023
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
85,317
+24.39%
|
$0
$0.84 P/Share
|
|
Jan 24
2023
|
James K Fong EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
100,000
-96.56%
|
$600,000
$6.0 P/Share
|
|
Jan 24
2023
|
James K Fong EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+49.12%
|
$0
$0.95 P/Share
|
|
Jan 03
2023
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
84,683
-74.2%
|
$508,098
$6.01 P/Share
|
|
Jan 03
2023
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
84,683
+42.6%
|
$0
$0.84 P/Share
|
|
Jan 03
2023
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,021
-61.21%
|
$162,126
$6.01 P/Share
|
|
Jan 03
2023
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,021
+37.97%
|
$0
$0.95 P/Share
|
|
Dec 30
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
17,100
-14.76%
|
$102,600
$6.0 P/Share
|
|
Dec 30
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,100
+12.08%
|
$0
$0.84 P/Share
|
|
Dec 30
2022
|
Adam R Craig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,579
+5.09%
|
$7,895
$5.11 P/Share
|
|
Dec 30
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,847
-17.14%
|
$83,082
$6.0 P/Share
|
|
Dec 30
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,847
+12.97%
|
$0
$0.95 P/Share
|